P5-14-02: Clinicopathologic and Prognostic Difference of Screen Detected Breast Cancer Compared with Symptomatic Breast Cancer.

Abstract

Abstract Background: Breast cancer screening program makes it possible to detect early cancer, thus to reduce breast cancer mortality. The authors studied clinicopathologic characteristics and prognosis of screen detected invasive breast cancer compared with symptomatic breast cancer. Furthermore, we compared the result according to molecular subtypes (luminal A, luminal B, Her2, triple negative), so intended to identify the role of screening in each subtypes. Material and Methods: From January 2002 to June 2008, 3141 patients who underwent operation for the treatment of invasive ductal carcinoma(NOS) at Samsung medical center were included. Among them, 1025 patient were screen detected, 2116 patient were symptomatic, out of screening over 2 years. We reviewed the medical records retrospectively. Result: Screen detected breast cancer was associated with older patients, smaller tumor size, more hormone receptor- positive, less lymph node involvement, lower stage and reduced mortality compared with symptomatic breast cancer (P < .001). According to the molecular subtype, in luminal A subtype, the result shows better pathologic feature and also favorable overall and recur-free survial significantly. Conclusion: Compared to symptomatic breast cancer patients, screen detected breast cancer patients have favorable pathological and molecular characteristics, so better outcomes. According to the molecular subtype, only in luminal A subtype, screen detected breast cancer shows both overall and disease free survival benefit, and also acts as an independent prognostic factor itself. So, screening program seems to have a different efficacy depending on the molecular subtype of breast cancer Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-14-02.